Editorial Medicalfacts/ Janine Budding 25 August 2023 – 19:30
Results from a phase 3 trial called STEP HFpEF were presented today at the European Society of Cardiology (ESC) Congress. The study shows that a weekly dose of 2.4 mg semaglutide produced significant improvements in adults with heart failure with preserved ejection fraction (HFpEF) and obesity. Study participants who received the semaglutide dose showed large reductions in symptoms related to heart failure, physical limitations and improvements in their ability to move. In addition, the treatment resulted in significant weight loss.
HFpEF accounts for approximately half of all heart failure cases and is characterized by a high disease burden and physical limitations that affect daily life, including fatigue, shortness of breath, reduced ability to move and edema in the extremities. The majority of people with HFpEF are also overweight or obese, which is associated with a higher burden of symptoms and a reduced quality of life.
The findings were presented at the European Society of Cardiology (ESC) Congress in Amsterdam, the Netherlands, and published simultaneously in the New England Journal of Medicine. The study showed significant improvements in HFpEF symptoms and physical limitations as measured by the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS).
Doctors are positive about the results, as there are currently limited treatment options for patients with HFpEF and obesity. Dr. Mikhail Kosiborod, principal investigator of the study, emphasizes that these findings could potentially change cardiologists’ approach to HFpEF in obese people.
In addition to improvements in symptoms and physical function, the study also showed significant weight loss in participants who received the semaglutide dose compared to those who received a placebo. In addition, an increase in walking distance and a decrease in inflammation were observed in the semaglutide group.
The safety profiles of the treatment were similar to previous studies. Less serious side effects were observed in participants who received semaglutide.
HFpEF is a common form of heart failure and is often associated with being overweight or obese. Despite advances in the treatment of HFpEF, unmet needs remain for this patient population. The research hopes to contribute to a better understanding of this condition and how to manage it more effectively.
This research was funded by Novo Nordisk
Editorial Medicalfacts/ Janine Budding
I studied physiotherapy and Health Care business administration. I am also a registered independent client support worker and informal care broker. I have a lot of experience in various positions in healthcare, the social domain and the medical, pharmaceutical industry, nationally and internationally. And have broad medical knowledge of most healthcare specialties. And of the care laws from which the care is regulated and financed. Every year I attend most of the leading medical conferences in Europe and America to keep my knowledge up-to-date and to keep up with the latest developments and innovations. Currently I am doing a Masters in Applied Psychology.
My posts on this blog do not reflect the strategy, policy or direction of any employer, nor are they work by or for any client or employer.
2023-08-25 17:33:11
#Significant #improvement #demonstrated #STEP #HFpEF #study #MedicalFacts.nl
